About Amgen

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.

How Amgen supported IgG4ward!

Our partnership with Amgen led to the first international clinical trial ever performed in IgG4-RD. The trial, named MITIGATE, was a landmark moment for IgG4ward!, Amgen and patients living with this rare disease. The MITIGATE trial enrolled patients from 22 different countries to participate in a B cell depletion medicine called inebilizumab. The completion of this stage 3 clinical trial revealed that inebilizumab reduced the risk of IgG4-RD flare by 87% compared to the standard treatment arm. While much work remains ahead, IgG4-RD patients now have access to an effective FDA-approved drug.